Unveiling B7-H3 as novel target for CAR T-cell therapy in Multiple Myeloma

Chimeric Antigen Receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) has demonstrated impressive response rates in the treatment of multiple myeloma (MM), yet durable cures are rare due to T-cell exhaustion and the emergence of BCMA-negative subpopulations. To tackle the latter, we present evidence supporting B7-H3 as a promising target for immunotherapy in MM.

We developed nanobody-based CAR T cells targeting B7-H3, referred to as nanoCAR T cells. These nanoCAR T cells demonstrate potent antigen-specific cytotoxicity and cytokine secretion in vitro, and robust anti-tumor activity in preclinical mouse models.

This study underscores the potential of B7-H3 as a therapeutic target for nanoCAR T-cell therapy, complementing BCMA-targeted approaches and offering a strategy to mitigate relapse in MM.